Last Updated : April 26, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Prexige | Lumiracoxib | Osteoarthritis (Knee) | Do not list | Complete | ||
Prezcobix | Darunavir/cobicistat | HIV Infection | List with criteria/condition | Complete | ||
Prezista | Darunavir | HIV (treatment naive) | List with clinical criteria and/or conditions | Complete | ||
Prezista | Darunavir | HIV infection (Pediatric) | List with clinical criteria and/or conditions | Complete | ||
Prezista | Darunavir | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Pristiq | Desvenlafaxine succinate | Depressive, Major Disorder (MDD) | Do not list | Complete | ||
Probuphine | buprenorphine hydrochloride | Opioid drug dependence, treatment | Reimburse with clinical criteria and/or conditions | Complete | ||
Procysbi | cysteamine bitartrate | Nephropathic cystinosis | Reimburse with clinical criteria and/or conditions | Complete | ||
Proleukin | Aldesleukin (IL-2) | In-transit Melanoma | Reimburse | Complete | ||
Prolia | Denosumab (Drug Plan Submission) | Osteoporosis, men | List with clinical criteria and/or conditions | Complete |